RxDoctor Payments Data

Carlos Bayron, MD

Interventional Cardiology · Clearwater, FLNPI 1538157227

Payments from drug & device makers

$20,122in general payments, 2019–2025

Across 371 payments — averaging $54.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$7K
  • Siemens Medical Solutions USA, Inc.$5K
  • Medtronic$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$834
  • Boston Scientific$724
  • Abbott$618
  • plus $5K from 33 others

What the payments were for

  • Consulting fees$5,00034%
  • Travel & lodging$9467%
  • Food & beverage$8,33257%
  • Education$2161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,122 in reported general payments places this provider in the 65th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$343,538
Medicare patients
1,515
Services billed
3,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$122,104
XareltoRivaroxaban57$74,183
EntrestoSacubitril/Valsartan51$53,084
BrilintaTicagrelor52$43,200
Repatha SureclickEvolocumab39$35,380
FarxigaDapagliflozin Propanediol25$29,787
MultaqDronedarone Hcl18$25,621
NexletolBempedoic Acid14$9,229
Prasugrel Hcl36$5,609
Propafenone Hcl46$4,591
Metoprolol Succinate234$3,341
ClopidogrelClopidogrel Bisulfate340$3,183
Clonidine13$1,874
Rosuvastatin Calcium163$1,811
Flecainide Acetate14$1,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$187$122,104113 claims
Johnson & JohnsonXarelto$576$74,18357 claims
AstraZenecaBrilinta, Farxiga$6,640$72,98777 claims
NovartisEntresto$378$53,08451 claims
Sanofi-aventis U.S. LLCMultaq$125$25,62118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →